Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of atezolizumab versus placebo with paclitaxel, carboplatin, and bevacizumab in newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer
MOH_2017-12-25_002014Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Bevacizumab + atezolizumab with Bevacizumab + atezolizumab placebo (2 arms). Planned start Nov 2017; status: not yet recruiting.
02
Drugs
atezolizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2017-12-25_002014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-25_002014.